Actively Recruiting
Safety of Robotic Surgery for GISTs at Special Anatomic Sites
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2026-02-12
182
Participants Needed
1
Research Sites
173 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a prospective, multicenter, single-arm, phase II clinical trial. It plans to enroll 182 patients with localized gastric gastrointestinal stromal tumors (GISTs) at special anatomic sites. Eligible patients who meet the inclusion/exclusion criteria and provide written informed consent will undergo robotic radical surgery. Postoperative treatment will be determined jointly by the clinicians and patients based on actual clinical practice.
CONDITIONS
Official Title
Safety of Robotic Surgery for GISTs at Special Anatomic Sites
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 75 years, regardless of sex.
- Diagnosis of GIST at a special anatomic site confirmed by endoscopy, CT, or MRI.
- Tumor size between 2 cm and 5 cm based on preoperative imaging.
- No prior neoadjuvant therapy such as imatinib.
- Expected survival of at least 6 months.
- Assessed as suitable for robotic surgery.
- No distant metastasis or invasion into adjacent organs.
- ECOG Performance Status score of 0 or 1.
- ASA Physical Status classification between I and III.
- Provided written informed consent after understanding study information.
You will not qualify if you...
- Previous upper abdominal surgery except laparoscopic cholecystectomy.
- History of gastrectomy, endoscopic mucosal resection, or submucosal dissection.
- Prior neoadjuvant therapy such as imatinib.
- Other active cancers within the past 5 years or currently, except certain cured localized tumors.
- Need for surgery for other diseases at the same time.
- Emergency surgery due to tumor complications like bleeding or obstruction.
- Thrombotic events like stroke or deep vein thrombosis within 6 months prior.
- Recent myocardial infarction or poorly controlled arrhythmia.
- Severe heart failure or reduced heart pumping function.
- Ventilatory dysfunction with FEV1 below 50% predicted.
- Symptomatic pleural or abdominal fluid requiring treatment.
- HIV infection.
- Active pulmonary tuberculosis.
- History or presence of severe lung diseases affecting detection or treatment.
- Active infections needing systemic treatment within 14 days before surgery (except prophylactic antibiotics).
- Participation in other surgical clinical trials.
- History of substance abuse.
- Likely non-compliance with treatment or incomplete data.
- Pregnant or lactating women.
- Any other condition increasing risk or judged unsuitable by investigators.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital)
Nanjing, Jiangsu, China
Actively Recruiting
Research Team
Q
Qiang Zhang, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here